Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue (2010 - 2011)
Madrigal Pharmaceuticals (MDGL) reported Current Deferred Revenue of $3.3 million for Q3 2011, down 25.71% quarter-over-quarter from $4.4 million in Q2 2011.
Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue (2010 - 2011) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 2 years of Current Deferred Revenue data on file, last reported at $3.3 million in Q3 2011.
- Current Deferred Revenue for Q3 2011 came in at $3.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2011 was $3.3 million (changed N/A YoY), and the FY2010 annual result was $4.6 million, changed N/A from the prior year.
- Current Deferred Revenue eased to $3.3 million in Q3 2011 per MDGL's latest filing, from $4.4 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $4.6 million in Q4 2010 and troughed at $3.3 million in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 3.30 Mn |
| Jun 30, 2011 | 4.45 Mn |
| Dec 31, 2010 | 4.57 Mn |